Arcus Biosciences, Inc. — Director's Dealing 2018

Mar 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2018-03-19

Reporting Person: ROSEN TERRY J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-19	Common Stock	C	2475654	—	Acquired	3818078	Indirect
2018-03-19	Common Stock	P	66666	$15.00	Acquired	3884744	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-19	Series A Convertible Preferred Stock	$	C	2267676	Disposed		Common Stock (2267676)	Indirect
2018-03-19	Series B Convertible Preferred Stock	$	C	125012	Disposed		Common Stock (125012)	Indirect
2018-03-19	Series C Convertible Preferred Stock	$	C	82966	Disposed		Common Stock (82966)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	189393	Direct

Footnotes

F1: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.

F2: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F3: Represents shares purchased in the Issuer's initial public offering.

F4: The total includes 126,262 shares of Common Stock acquired by the Reporting Person on January 12, 2018 for $5.39 per share pursuant to the exercise of an option granted on January 4, 2018.

F5: Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.